Nature Reviews Clinical Oncology

Article	Citations
Nirogacestat effective in desmoid tumours	1061
Enfortumab vedotin is safe and effective	721
HSCT prolongs remission of high-risk CTCLs	717
Whole-genome sequencing for myeloid disease: one assay to stratify them all?	686
Combination improves salvage outcomes	611
Emerging clinical applications of single-cell RNA sequencing in oncology	578
Thermal ablation is safer than resection of colorectal liver lesions	563
SOX superior to CAPOX in resectable G/GEJ cancer	550
Hodgkin lymphoma: great progress with room for improvement	528
Practicing on the edge of oncology: when standard of care feels uncomfortable	517
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	512
Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer	509
Copanlisib safe and active in combination	509
New insights from recurrence score	455
Promising OS with oncolytic virotherapy	454
Adjuvant pembrolizumab improves overall survival in patients with RCC	434
Novel ICI–TKI combination improves HCC outcomes	422
Uncovering adagrasib resistance	417
Cemiplimab is a new option in BCC	376
Adjuvant pembrolizumab shows promise	328
BrECADD raises the bar in classical Hodgkin lymphoma	326
NICHE-2 validates the efficacy of neoadjuvant ICIs in dMMR colon cancer	317
Capivasertib delays disease progression	316
HSP90 inhibition improves GIST survival	309
Tasadenoturev active in DIPG	307

From ASCO 2023	306
Abemaciclib crowned in monarchE	299
GPRC5D-CAR T cells active in MM	283
Dabrafenib–trametinib moves to the first line in low-grade glioma	270
Efficacy of TILs confirmed	269
Promise with co-administration of CAR T cells	265
A new standard of care for advanced-stage urothelial carcinoma	247
Pegargiminase improves outcomes in nonepithelioid MPM	245
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	242
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	236
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	233
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care	233
Lack of benefit from extended lymphadenectomy in muscle-invasive bladder cancer	229
From little subclones grow mighty oaks	215
Finding the Goldilocks zone in neoadjuvant radioimmunotherapy	202
Adjuvant olaparib — should all patients with breast cancer have genetic testing?	198
Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy	195
Is NETTER-2 a practice-changing trial?	194
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks	189
Should the control arms of randomized trials have an expiry date?	189
Applications of cell therapy in the treatment of virus-associated cancers	188
HPV-associated oropharyngeal cancer — discussion points	188
Reply to ‘NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3’	183
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	182
A new era for glioma therapy — targeting mutant IDH	179
CAR T cells in multiple myeloma: lessons learned	176
Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies	166
Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis	165
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	164
Cerebrospinal fluid liquid biopsies for medulloblastoma	158
Immunotherapy approaches for malignant pleural mesothelioma	157
‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent	152
Anaplastic glioma: benefit of temozolomide clarified	150
Gut microbes as biomarkers of ICI response — sharpening the focus	150
From ASCO 2022	146
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety	140
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	140
Functional precision oncology using patient-derived assays: bridging genotype and phenotype	134
Value-based pricing of drugs with multiple indications or in combinations — lessons from Europe	133
International approvals of cilta-cel: a lens on CAR T cell regulation	133
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma	129
Nucleic acid-based drugs for patients with solid tumours	126
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	124
Targeting cuproplasia and cuproptosis in cancer	109
Molecular tumour boards — current and future considerations for precision oncology	108
Beneficial autoimmunity improves cancer prognosis	103
Sotorasib dosing and incremental cost ineffectiveness — implications and lessons for stakeholders	101
Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer	99
Nasopharyngeal carcinoma: an evolving paradigm	97
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	97

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management	97
The immune landscape of common CNS malignancies: implications for immunotherapy	96
New treatment strategies for advanced-stage gastrointestinal stromal tumours	95
Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination	95
KEYNOTE-355 — OS benefit now reported	92
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion	91
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma	88
Gut microbiota in colorectal cancer development and therapy	86
The emerging roles of circRNAs in cancer and oncology	84
Exploring the next generation of antibody–drug conjugates	84
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	83
Current understanding and management of CAR T cell-associated toxicities	81
Exploiting bacteria for cancer immunotherapy	78
The current state of the art and future trends in RAS-targeted cancer therapies	77
Dostarlimab effective in dMMR LARC	75
Belzutifan has potential in RCC	74
Non-inferiority of simple versus radical hysterectomy in low-risk cervical cancer	73
Belzutifan is active in VHL-related cancers	73
Zolbetuximab moves into the SPOTLIGHT	69
CAR T cells show activity	67
Addition of sintilimab to standard therapy improves event-free survival	65
CAR T cells show promise in mesothelioma	65
SUNLIGHT illuminates the activity of bevacizumab	63
Pembrolizumab tunes up chemotherapy in cervical cancer	61
A triple dose of optimism: an initial foray into triplet therapy in metastatic renal cell carcinoma	61
Brentuximab vedotin improves outcomes	61
A critical appraisal of the ATLAS trial of maintenance therapy for multiple myeloma: end points, censoring and equipoise	57
Neoadjuvant pembrolizumab improves outcomes	56
Synergy of EphB2 and PD-1 blockade	51
Mortality is similar with active monitoring	51
Using oncolytic viruses to induce hyperacute rejection against cancer	50
Early intervention with daratumumab improves survival for patients with high-risk smouldering myeloma	50
Sacituzumab govitecan is safe and effective	50
ROAR brings in a new histology-agnostic approval for rare cancers	48
T-DXd improves PFS versus T-DM1	47
Neoadjuvant pembrolizumab shows promise in MSI-H/dMMR solid tumours	45
Cytoreductive surgery effective after relapse	44
Blinatumomab improves outcomes in adult MRD-negative BCP-ALL	44
Contrasting results with second-line CAR T cells in large B cell lymphoma	44
Benefit with adjuvant metronomic capecitabine in NPC	42
Ponatinib superior to imatinib in Ph+ ALL	40
MSI-H/dMMR mCRC: ICIs in the first line?	39
The promise of AI in personalized breast cancer screening: are we there yet?	38
IL-13Rα2-targeted CAR T cells show promise in patients with recurrent high-grade gliomas	38
Dabrafenib–trametinib is effective in paediatric high-grade glioma	38
From AACR 2024	37
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	34
Repotrectinib effective in ROS1-fusion-positive NSCLC	34
Newly diagnosed AML: quizartinib improves OS	31
Adjuvant immunotherapy for NSCLC — does treating earlier mean treating better?	31
177Lu–PSMA-PET extends survival	31
LAG3 inhibition improves outcomes	30
Optimal systemic therapy for high-risk resectable melanoma	29
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions	28
From ESMO 2022	25
Author Correction: Anaplastic glioma: benefit of temozolomide clarified	25
From the ESMO Congress 2021	24
On the cusp of targeted therapy for cancer cachexia — what clinical benefits might we promise our patients?	24
Benefit with glofitamab plus chemotherapy in transplant-ineligible R/R DLBCL	23
The TOPGEAR trial — is chemoradiotherapy no longer a component of multidisciplinary care for gastric cancer?	23
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	22
Understanding and overcoming resistance to PARP inhibitors in cancer therapy	21
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	21
Systemic therapy for early-stage breast cancer: learning from the past to build the future	19
Integrated MRI-guided radiotherapy — opportunities and challenges	19
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed	18
Radiotheranostics in oncology: current challenges and emerging opportunities	18
Enhancing diagnostic precision in liver lesion analysis using a deep learning-based system: opportunities and challenges	18
Ensuring completeness and timeliness of cancer treatment guidelines	17
Predicting tumour origin with cytology-based deep learning: hype or hope?	16
Determinants of response and resistance to T cell-engaging therapies in multiple myeloma	14
TNT and local recurrence in the RAPIDO trial — untangling the puzzle	14
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	14
The MARIPOSA trials — implications for the treatment of EGFR-mutant NSCLC	13
Digital symptom assessment tools: the next frontier in financial toxicity screening	13
NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3	12
Redefining priorities: a call for patient-centred cancer care and research	12
FDA approvals in 2023: biomarker-positive subsets, equipoise and verification of benefit	12
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins	11
KN046 shows tolerability and activity in TNBC	11

Minimal residual disease as a target for liquid biopsy in patients with solid tumours	11
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer	11
The FDA’s latest move to expand eligibility for oncology trials — a double-edged sword?	11
Advancing CAR T cell therapy through the use of multidimensional omics data	11
Criteria for the translation of radiomics into clinically useful tests	10
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	10
Advancing therapy for osteosarcoma	10
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions	10
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer	10
Bispecific and multispecific antibodies in oncology: opportunities and challenges	10
Problematic crossovers in cancer drug trials	10
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes	9
Neoadjuvant therapy for pancreatic cancer	8
Humanized mouse models for immuno-oncology research	8
The emerging roles of γδ T cells in cancer immunotherapy	8
Tumour mutational burden: clinical utility, challenges and emerging improvements	8
The emerging role of photoacoustic imaging in clinical oncology	8
TAM family kinases as therapeutic targets at the interface of cancer and immunity	8
Predicting cancer outcomes with radiomics and artificial intelligence in radiology	7
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management	7
Fundamentals and developments in fluorescence-guided cancer surgery	7
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy	7
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs	6
Blinatumomab improves outcomes in infant ALL	6
Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma	6
GPRC5D as a novel immunotherapeutic target in multiple myeloma	6
Circulating tumour cells for early detection of clinically relevant cancer	6
Harnessing cytokines and chemokines for cancer therapy	6
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL	5
Darolutamide combo is a sensible option for mHSPC	5
Adjuvant osimertinib improves overall survival	5
Prospective insights on the use of bTMB	5
Maintenance capecitabine is beneficial in NPC	5
T-DXd effective in HER2-mutant NSCLC	5
A cfDNA-based approach is feasible	4
HSV-1 G207 is active in paediatric glioma	4
Adjuvant S-1 extends OS in biliary tract cancers	4
Prospective clinical deployment of machine learning in radiation oncology	4
Defining clinically important overall survival thresholds: lessons from quality of life	4
Safety of interrupting adjuvant endocrine therapy to conceive: early data are POSITIVE	4
The SONIA trial shows the power and challenges of academic research	4
Engaging results with glofitamab	4
KTE-X19 efficacious in adults with B-ALL	4
BFAST but be smart: bTMB remains an exploratory biomarker in NSCLC	4
Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL	4
When an embarrassment of riches isn’t enough	4
MRI-based stratification reduces the risk of overdiagnosis of prostate cancer	4
National value-based pricing negotiation for oncology drugs — lessons from China	4
Reply to ‘HPV-associated oropharyngeal cancer — discussion points’	4
Author Correction: EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment	4
ALND can be safely omitted for patients with sentinel-node macrometastases	3
T-DXd active in HER2-low disease	3
Craniospinal irradiation improves leptomeningeal metastasis control	3
Survival benefit with second-line combination in endometrial cancer	3
New combination therapy for advanced-stage RCC	3
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs	3
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges	3
New data confirm clinical utility of ctDNA	3
Activity of selpercatinib confirmed in phase III trials	3
Frontline nivolumab combinations improve OS in ESCC	3
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours	3
Promising early results with CAR NK cells	3
CAR T cells induce durable remission of neuroblastoma	3
Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?	3
Author Correction: Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response	3
CAR T cells show promise in the frontline for high-risk LBCL	3
Asciminib is safe and effective in patients with newly diagnosed CML	3
Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma	3
BRAF plus MEK inhibition effective in papillary craniopharyngioma	3
Biliary tract cancer: frontline pembrolizumab hits KEYNOTE	3
Telemedicine as patient-centred oncology care: will we embrace or resist disruption?	3
Combination strategies for advanced-stage urothelial carcinoma: a paradigm shift	3
Targeting ATR in patients with cancer	2
PERSEUS triumphs — efficacy of daratumumab confirmed in transplant-eligible NDMM	2
Irradiation of asymptomatic bone metastases improves outcomes	2
From ESMO 2023: advances in lung cancer	2
Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine	2
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains	2
Tumour antigen-induced T cell exhaustion — the archenemy of immune-hot malignancies	2
Therapeutic targeting of the hypoxic tumour microenvironment	2
Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070	2
Neoadjuvant chemoimmunotherapy is effective in locally advanced cervical cancer	2
Camrelizumab efficacious in NPC	2
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours	2
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	2
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment	2
Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention	2
Personalizing adjuvant therapy for patients with colorectal cancer	2
Targeting chromosomal instability in patients with cancer	2
Adjuvant chemotherapy improves OS in UTUC	2
Tebentafusp for uveal melanoma	2
New CAPSTONE of SCLC therapy?	2
Targeting drugs to tumours using cell membrane-coated nanoparticles	2
Afami-cel provides a novel treatment option for rare sarcoma subtypes	2
Towards precision oncology with patient-derived xenografts	2